Copenhagen, 2013-05-21 15:00 CEST (GLOBE NEWSWIRE) --
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”), a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, informs it will present at the following upcoming healthcare investor conferences in the United States:
Deutsche Bank 38th Annual Healthcare Conference, Boston (29-31 May 2013)
Presentation time: 4:10pm ET, 29 May 2013
Presenter: David H. Solomon, President and CEO of Zealand
Jefferies Global Healthcare Conference, NYC (3-6 June 2013)
Presentation time: 3:30pm ET, 3 June 2013
Presenter: David H. Solomon, President and CEO of Zealand
Please note that no new financial or other material new information relating to Zealand will be disclosed at the above listed conferences.
***
For further information, please contact:
Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About ZealandZealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved in Europe (February 2013) under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2012).
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. For further information: www.zealandpharma.com
